Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News: Sep 30, 2010

Premium

Meridian Bioscience said this week that Health Canada has granted the company an approved medical device license for illumigene C. difficile, the company's Clostridium difficile molecular amplification assay.

The assay amplifies DNA using loop amplification technology to detect the presence of the toxin-producing region from the bacterium. Meridian said that the test provides highly accurate results in under an hour.

In July, Meridian received clearance from the US Food and Drug Administration to sell the test (PCR Insider, 7/15/2010). The company said it has also successfully launched the test in Australia, Taiwan, and most European markets.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.